China NMPA Grants IND Clearance to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer

Follows initiation of Phase 1a/1b study in the U.S. Adcentrx intends to include clinical centers in China to broaden geographic representation and accelerate patient enrollment into the Phase 1a/1b study SAN DIEGO and SHANGHAI, June 8, 2026 /PRNewswire/ -- Adcentrx Therapeutics...